These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1183 related articles for article (PubMed ID: 19469698)

  • 1. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada.
    Paes B; Cole M; Latchman A; Pinelli J
    Curr Med Res Opin; 2009 Sep; 25(9):2191-6. PubMed ID: 19604126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA; Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation.
    Sampalis JS; Langley J; Carbonell-Estrany X; Paes B; O'Brien K; Allen U; Mitchell I; Aloy JF; Pedraz C; Michaliszyn AF
    Med Decis Making; 2008; 28(4):471-80. PubMed ID: 18556643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory syncytial virus risk factors in late preterm infants.
    Lanari M; Silvestri M; Rossi GA
    J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.
    Pediatrics; 1998 Sep; 102(3):531-7. PubMed ID: 9724660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.